Stockreport

argenx launches Phase I trial with subcutaneous formulation of ARGX-113

argenx SE - American Depositary Shares  (ARGX) 
PDF Subcutaneous formulation intended for chronic therapy setting October 30, 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a cl [Read more]